出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/10/20 03:36:43」(JST)
| Neuronal ceroid lipofuscinosis | |
|---|---|
| Classification and external resources | |
| Specialty | endocrinology |
| ICD-10 | E75.4 |
| ICD-9-CM | 330.1 |
| MedlinePlus | 001613 |
| eMedicine | neuro/498 |
| MeSH | D009472 |
Neuronal ceroid lipofuscinoses (NCL) is the general name for a family of at least eight genetically separate neurodegenerative disorders that result from excessive accumulation of lipopigments (lipofuscin) in the body's tissues. These lipopigments are made up of fats and proteins. Their name comes from the word stem lipo-, which is a variation on "lipid" or "fat", and from the term pigment, used because the substances take on a greenish-yellow color when viewed under an ultraviolet light microscope. These lipofuscin materials build up in neuronal cells and many organs, including the liver, spleen, myocardium, and kidneys.
The classic characterization of the group of neurodegenerative, lysosomal storage disorders called the neuronal ceroid lipofuscinoses (NCLs) is through the progressive, permanent loss of motor and psychological ability with a severe intracellular accumulation of lipofuscins,[1][2] with the United States and northern European populations having slightly higher frequency with an occurrence of 1 in 10,000.[3] There are four classic diagnoses that have received the most attention from researchers and the medical field, differentiated from one another by age of symptomatic onset, duration, early-onset manifestations such as blindness or seizures, and the forms which lipofuscin accumulation takes.[1]
In the early infantile variant of NCL (also called INCL or Santavuori-Haltia), probands appear normal at birth, but early visual loss leading to complete retinal blindness by the age of 2 years is the first indicator of the disease; by 3 years of age a vegetative state is reached and by 4 years isoelectric encephalograms confirm brain death. Late infantile variant usually manifests between 2 and 4 years of age with seizures and deterioration of vision. The maximum age before death for late infantile variant is 10–12 years.[4][5][6][7] Juvenile NCL (JNCL, Batten Disease, or Spielmeyer-Vogt), with a prevalence of 1 in 100,000, usually arises between 4 and 10 years of age; the first symptoms include considerable vision loss due to retinal dystrophy, with seizures, psychological degeneration, and eventual death in the mid- to late-20s or 30s ensuing.[8] Adult variant NCL (ANCL or Kuf’s Disease) is less understood and generally manifests milder symptoms; however, while symptoms typically appear around 30 years of age, death usually occurs ten years later.[9]
All the mutations that have been associated with this disease have been linked to genes involved with the neural synapses metabolism – most commonly with the reuse of vesicle proteins.
The first probable instances of this condition were reported in 1826 in a Norwegian medical journal by Dr. Christian Stengel,[10][11][12][13] who described 4 affected siblings in a small mining community in Norway. Although no pathological studies were performed on these children the clinical descriptions are so succinct that the diagnosis of the Spielmeyer-Sjogren (juvenile) type is fully justified.
More fundamental observations were reported by F. E. Batten in 1903,[14] and by Heinrich Vogt in 1905,[15] who performed extensive clinicopathological studies on several families. Retrospectively, these papers disclose that the authors grouped together different types of the syndrome. Furthermore Batten, at least for some time, insisted that the condition that he described was distinctly different from Tay-Sachs disease, the prototype of a neuronal lysosomal disorder now identified as GM2 gangliosidosis type A. Around the same time, Walther Spielmeyer reported detailed studies on three siblings,[16] suffering from the Spielmeyer-Sjogren (juvenile) type, which led him to the very firm statement that this malady is not related to Tay-Sachs disease. Subsequently, however, the pathomorphological studies of Károly Schaffer made these authors change their minds to the extent that they reclassified their respective observations as variants of Tay-Sachs disease, which caused confusion lasting about 50 years.
In 1913–14, Max Bielschowsky delineated the late infantile form of NCL.[17] However, all forms were still thought to belong in the group of "familial amaurotic idiocies", of which Tay-Sachs was the prototype.
In 1931, Torsten Sjögren, the Swedish psychiatrist and geneticist, presented 115 cases with extensive clinical and genetic documentation and came to the conclusion that the disease which we now call the Spielmeyer-Sjogren (juvenile) type is genetically separate from Tay-Sachs.[18]
Departing from the careful morphological observations of Spielmeyer, Hurst, and Sjovall and Ericsson, Zeman and Alpert made a determined effort to document the previously suggested pigmentary nature of the neuronal deposits in certain types of storage disorders.[19] Simultaneously, Terry and Korey[20] and Svennerholm[21] demonstrated a specific ultrastructure and biochemistry for Tay-Sachs disease, and these developments led to the distinct identification and also separation of the NCLs from Tay-Sachs disease by Zeman and Donahue. At that time, it was proposed that the Late Infantile (Jansky-Bielschowsky), the juvenile (Spielmeyer-Vogt), and the adult form (Kufs) were quite different from Tay-Sachs disease with respect to chemical pathology and ultrastructure and also different from other forms of sphingolipidoses.
Subsequently, it was shown by Santavuori and Haltia that an infantile form of NCL exists,[22] which Zeman and Dyken had included with the Jansky Bielschowsky type.
The older classification of NCL divided the condition into four types (CLN1, CLN2, CLN3, and CLN4) based upon age of onset, while newer classifications divide it by the associated gene.[23][24]
CLN4 (unlike CLN1, CLN2, and CLN3) has not been mapped to a specific gene.
| Type | Description | OMIM | Gene |
| Type 1 | Infantile NCL (Santavuori-Haltia disease, INCL): begins between about 6 months and 2 years of age and progresses rapidly. Affected children fail to thrive and have abnormally small heads (microcephaly). Also typical are short, sharp muscle contractions called myoclonic jerks. Initial signs of this disorder include delayed psychomotor development with progressive deterioration, other motor disorders, or seizures. The infantile form has the most rapid progression and children live into their mid childhood years. The gene responsible for Infantile NCL has been identified in some cases of juvenile/adult onset. It is thought these patients have some partial enzyme production that leads to a protracted, less severe disease course. | 256730 | PPT1 |
| Type 2 | Late Infantile NCL (Jansky-Bielschowsky disease, LINCL) begins between ages 2 and 4. The typical early signs are loss of muscle coordination (ataxia) and seizures along with progressive mental deterioration, though afflicted children may show mild-severe delays in speech development well before other symptoms appear. This form progresses rapidly and ends in death between ages 8 and 12. | 204500 | TPP1 |
| Type 3 | Juvenile NCL (Batten disease, JNCL) begins between the ages of 5 and 8 years of age. The typical early signs are progressive vision loss, seizures, ataxia or clumsiness. This form progresses less rapidly and ends in death in the late teens or early 20s, although some have been known to live into their 30s. | 204200 | CLN3 |
| Type 4 | Adult NCL (Kufs disease, ANCL) generally begins before the age of 40, causes milder symptoms that progress slowly and does not cause blindness. Although age of death is variable among affected individuals, this form does shorten life expectancy. | 204300 (AR), 162350 (AD) | CLN6[25] DNAJC5 |
| Type 5 | Finnish Late Infantile (Finnish Late Infantile Variant, vLINCL) – identified in Finland. | 256731 | CLN5 |
| Type 6 | Variant Late Infantile (Late Infantile Variant, vLINCL) – identified in Costa Rica, South America, Portugal, the United Kingdom and other nations. | 601780 | CLN6 |
| Type 7 | CLN7 | 610951 | MFSD8 |
| Type 8 | CLN8 Northern Epilepsy, progressive epilepsy with mental retardation (EPMR) | 610003 | CLN8 |
| Type 8 | Turkish Late Infantile (Turkish Late Infantile Variant,vLINCL) – identified in Turkey. | 600143 | CLN8 |
| Type 9 | Identified in Germany and Serbia. | 609055 | Unknown, but possibly regulator of dihydro-ceramide synthase[26] |
| Type 10 | CLN10 (Congenital, Cathepsin D Deficiency) | 116840 | CTSD |
Nonsense and frameshift mutations in the CLN1 gene (located at 1p32[27][28][29]) always induce classical INCL, while some misssense mutations have been associated with ANCL in addition to the Infantile and Juvenile forms. The mutation typically results in a deficient form of a lysosomal enzyme called palmitoyl protein thioesterase 1 (PPT1).[30]
The wild type PPT1 is a 306 amino acid polypeptide that is typically targeted for transport into lysosomes by the mannose 6-phosphate (M6P) receptor mediated pathway.[4][30] Here the protein appears to function in removing palmitate residues by cleaving thioester linkages in s-acylated (or palmitoylated) proteins, encouraging their breakdown.[4][5] Defective polypeptides, however, are unable to exit the endoplasmic reticulum (ER), most likely due to misfolding; further analyses of this pathway could serve to categorize INCL among lysosomal enzyme deficiencies. It is important to note that the human PPT gene shows 91% similarity to bovine PPT and 85% similarity to rat PPT; these data indicate that the PPT gene is highly conserved and likely plays a vital role in cell metabolism.[4] In addition buildup of defective PPT1 in the ER has been shown to cause the increased release of Ca2+. This homeostasis-altering event leads to increased mitochondrial membrane permeability and subsequent activation of caspase-9, eventually leading to an accumulation of cleaved and uncleaved poly(ADP-ribose) polymerase (PARP) and eventual apoptosis.[5]
The CLN2 gene encodes a 46kDa protein called lysosomal tripeptidyl peptidase I (TPPI) which cleaves tripeptides from terminal amine groups of partially unfolded proteins.[6][31][31] Mutations of this gene typically result in a LINCL phenotype.[32]
All mutations resulting in the Juvenile variant of NCL have been shown to occur at the CLN3 gene on 16p12;[28] of the mutations known to cause JNCL, 85% result from a 1.02 kb deletion, with a loss of amino acids 154–438, while the remaining 15% appear to result from either point or frameshift mutations.[8] The wild type CLN3 gene codes for a protein with no known function;[2] however, studies of the yeast CLN3 ortholog, the product of which is called Battenin (after its apparent connections to Batten’s Disease, or JNCL), have suggested that the protein may play a role in lysosomal pH homeostasis. Furthermore, recent studies have also implied the protein’s role in cathepsin D deficiency; the overexpression of the defective protein appears to have significant effects on cathepsin D processing, with implications suggesting that accumulation of ATP synthase subunit C would result.[33] Only recently have studies of human patients shown deficiency of lysosomal aspartyl proteinase cathepsin D.
Between 1.3% and 10% of cases are of the adult form. The age at onset is variable (6–62 yr). Two main clinical subtypes have been described: progressive myoclonus epilepsy (type A) and dementia with motor disturbances, such as cerebellar, extrapyramidal signs and dyskinesia (type B). Unlike the other NCLs retinal degeneration is absent. Pathologically the ceroid-lipofuscin accumulates mainly in neurons and contains subunit C of the mitochondrial ATP synthase.
Two independent families have been shown to have mutations in the DNAJC5 gene – one with a transvertion and the other with a deletion mutation.[34] The muations occur in a cysteine-string domain, which is required for membrane targeting/binding, palmitoylation and oligomerization of the encoded protein cysteine-string protein alpha (CSPα). The mutations dramatically decrease the affinity of CSPα for the membrane. A second report has also located this disease to this gene.[35]
Incidence can vary greatly from type-to-type, and from country-to-country.[36]
In Germany, one study reported an incidence of 1.28 per 100,000.[37]
A study in Italy reported an incidence of 0.56 per 100,000.[38]
A study in Norway reported an incidence of 3.9 per 100,000 using the years from 1978 to 1999, with a lower rate in earlier decades.[39]
Childhood NCLs are disordially autosomal recessive disorders; that is, they occur only when a child inherits two copies of the defective gene, one from each parent. When both parents carry one defective gene, each of their children faces one in four chance of developing NCL. At the same time, each child also faces a one in two chance of inheriting just one copy of the defective gene. Individuals who have only one defective gene are known as carriers, meaning they do not develop the disease, but they can pass the gene on to their own children.
Adult NCL may be inherited as an autosomal recessive (Kufs) or, less often, as an autosomal dominant (Parry's) disorder. In autosomal dominant inheritance, all people who inherit a single copy of the disease gene develop the disease. As a result, there are no unaffected carriers of the gene.
Because vision loss is often an early sign, Batten disease/NCL may be first suspected during an eye exam. An eye doctor can detect a loss of cells within the eye that occurs in the three childhood forms of Batten disease/NCL. However, because such cell loss occurs in other eye diseases, the disorder cannot be diagnosed by this sign alone. Often an eye specialist or other physician who suspects Batten disease/NCL may refer the child to a neurologist, a doctor who specializes in disease of the brain and nervous system. In order to diagnose Batten disease/NCL, the neurologist needs the patient's medical history and information from various laboratory tests.
Diagnostic tests used for Batten disease/NCLs include:
Currently there is no widely accepted treatment that can cure, slow down, or halt the symptoms of NCL. However, seizures may be controlled or reduced with use of anti-epileptic drugs. Additionally, physical, speech, and occupational therapies may help affected patients retain functioning for as long as possible.
Several experimental treatments are under investigation.
In 2001 it was reported a drug used to treat cystinosis, a rare genetic disease that can cause kidney failure if not treated, may be useful in treating the infantile form of NCL. Preliminary results report the drug has completely cleared away storage material from the white blood cells of the first six patients, as well as slowing down the rapid neurodegeneration of infantile NCL.
Currently there are two drug trials underway for infantile Batten disease/NCL. Both trials are using Cystagon.
A gene therapy trial using an adeno-associated virus vector called AAV2CUhCLN2 began in June 2004 in an attempt to treat the manifestations of Late Infantile NCL.[40] The trial was conducted by Weill Medical College of Cornell University[40] and sponsored by the Nathan's Battle Foundation.[41] In May 2008, it was reported that the gene therapy given to the recipients was "safe; and that, on average, it significantly slowed the disease's progression during the 18-month follow-up period"[42] and "suggested that higher doses and a better delivery system may provide greater benefit".[43]
A second gene therapy trial for Late Infantile NCL using an adeno-associated virus derived from rhesus macaque (a species of Old World monkey) called AAVrh.10 began in August 2010 and is once again being conducted by Weill Medical College of Cornell University.[43] Animal models of Late Infantile NCL showed that the AAVrh.10 delivery system "was much more effective, giving better spread of the gene product and improving survival greatly".[43]
A third gene therapy trial, using the same AAVrh.10 delivery system, began in 2011 and been expanded to include Late Infantile NCL patients with moderate/severe impairment or uncommon genotypes and uses a novel administration method that reduces general anesthesia time by 50% in order to minimize potential adverse side effects.[44]
A painkiller available in several European countries, Flupirtine, has been suggested to possibly slow down the progress of NCL,[45] particularly in the juvenile and late infantile forms. No trial has been officially supported in this venue, however. Currently the drug is available to NCL families either from Germany, Duke University Medical Center in Durham, North Carolina, and the Hospital for Sick Children in Toronto, Ontario.
On October 20, 2005, the Food and Drug Administration approved a phase I clinical trial of neural stem cells to treat infantile and late infantile Batten disease. Subsequent approval from an independent review board also approved the stem cell therapy in early March 2006. This treatment will be the first ever transplant of fetal stem cells performed on humans. The therapy is being developed by Stem Cells Inc and is estimated to have six patients. The treatment will be carried out in Oregon.[46]
Juvenile NCL has recently been listed on the Federal Clinical Trials website to test the effectiveness of bone marrow/stem cell transplants for this condition. A bone marrow transplant has been attempted in the late infantile form of NCL with disappointing results; while the transplant may have slowed the onset of the disease, the child eventually developed the disease and died in 1998.
Trials testing the effectiveness of bone marrow transplants for infantile NCL in Finland have also been disappointing, with only a slight slowing of disease reported.[47]
In late 2007, it was reported by Dr. David Pearce et al. that Cellcept, an immunosuppressant medication commonly used in bone marrow transplants, may be useful in slowing down the progress of Juvenile NCL.[48] Fundraising is currently underway to gather the funds needed to start a clinical trial to test the safety and efficiency of CellCept for Juvenile NCL.
There are more than eight variants of NCL, found in 1 in 12,500 people worldwide.
Late Infantile NCL (LINCL or Jansky-Bielschowsky), on the other hand, initially presents as generalized tonic-clonic or myoclonic seizures beginning at around 2–3 years of age; following this is depressed cognitive development including slow learning, speech delays, and eventual dementia leading to death, usually between 14 and 36 years of age.
Two mutations common to this gene are a G to C transversion and a C to T transition, which prematurely terminate translation at amino acid 208 of 563 (7). The deficiency of this lysosomal protease, then, results in increased subunit C storage.
|
||||||||||||||||||||||||||||||||||||||||||||||||||
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
| リンク元 | 「NCL」「神経性セロイドリボフスチノーシス」「神経元セロイドリポフスチン沈着症」 |
| 拡張検索 | 「neuronal ceroid-lipofuscinosis」「late infantile neuronal ceroid lipofuscinosis」 |
| 関連記事 | 「neuronal」「lipofuscinosis」 |
[★] 神経性セロイドリボフスチノーシス、neuronal ceroid lipofuscinosis